Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

HALO Relative to the S&P 500

HALO Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Halozyme Therapeutics Inc. (NASD:HALO) seasonal charts above shows that a Buy Date of June 8 and a Sell Date of September 18 has resulted in a geometric average return of 7.2% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success, but the return underperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 0.71% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

To download HALO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: HALO